Ten-year survival and risk of relapse for testicular cancer:: A EUROCARE high resolution study
Ten-year survival and risk of relapse for testicular cancer:: A EUROCARE high resolution study
复制标题
DOI：
10.1016/j.ejca.2006.11.006
复制
发表时间：
2007-02-01
影响因子：
8.4
通讯作者：
Tagliabue, Giovanna
中科院分区：
文献类型：
--
作者：
Sant, Milena;Aareleid, Tiiu;Tagliabue, Giovanna
自 20 世纪 70 年代以来，睾丸癌的有效治疗方法就已出现，但 EURO-CARE 发现该疾病的国家间生存率存在显着差异。为了调查这些差异，我们回顾了 1987 年至 1992 年期间诊断的 1350 例睾丸癌病例的临床记录，这些病例来自 9 个欧洲国家的 13 个基于人群的癌症登记处。对患者的生活状况和复发情况进行随访。通过 Kaplan-Meier 方法估计十年观察生存率。分别对精原细胞瘤和非精原细胞瘤进行 Cox 多变量分析。总体而言，66% 的精原细胞瘤和 36% 的非精原细胞瘤局限于睾丸。精原细胞瘤的十年生存率为 63%（爱沙尼亚）至 94%（瑞士、斯洛文尼亚）；非精原细胞瘤为 47%（爱沙尼亚）至 90%（约克郡、英国、荷兰）。根据国家、年龄和阶段进行调整的多变量分析表明，西欧登记处之间的死亡风险比 (HR) 差异不大，主要归因于诊断时的阶段不同。爱沙尼亚和波兰的 HR 显着高于参考值，表明治疗不足或不可用。 (c) 2006 Elsevier Ltd. 保留所有权利。
Effective treatments for testicular cancer have been available since the 1970s, yet EURO-CARE uncovered marked inter-country survival differences for this disease. To investigate these differences, we reviewed clinical records of 1350 testicular cancer cases diagnosed during 1987-1992 from 13 population-based cancer registries in nine European countries. Patients were followed up for life status and relapse. Ten-year observed survival was estimated by the Kaplan-Meier method. Cox multivariable analyses were performed separately for seminomas and non-seminomas. Overall, 66% of seminomas and 36% of non-seminomas were limited to the testis. Ten-year survival was 63% (Estonia) to 94% (Switzerland, Slovenia) for seminoma; 47% (Estonia) to 90% (Yorkshire, UK, The Netherlands) for non-seminoma. Multivariable analysis adjusted for country, age and stage showed that hazard ratios (HRs) of death differed little between western European registries, and were mainly attributable to differing stage at diagnosis. Significantly higher than reference HRs in Estonia and Poland suggest inadequacy or unavailability of treatments. (c) 2006 Elsevier Ltd. All rights reserved.